Mirum Pharmaceuticals Inc
MIRM51.900USD
-0.120-0.23%
交易中 （美東）報價延遲15分鐘
2.57B總市值
虧損本益比TTM
關於 Mirum Pharmaceuticals Inc 公司
Mirum Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於識別、收購、開發和商業化治療衰弱性罕見病和孤兒病的療法。該公司有三種藥物：LIVMARLI（maralixibat）口服溶液（Livmarli）、Cholbam（膽酸）膠囊和 Chenodal（chenodiol）片劑。Livmarli 是一種口服、最低吸收的迴腸膽汁酸轉運蛋白 (IBAT) 抑制劑 (IBATi)，用於治療美國和其他多個國家 Alagille 綜合徵 (ALGS) 患者的膽汁淤積性瘙癢以及美國進行性家族性肝內膽汁淤積 (PFIC) 患者的膽汁淤積性瘙癢。Cholbam 用於治療因單一酶缺乏引起的膽汁酸合成障礙和過氧化物酶體疾病的輔助治療。該公司還在推進其候選產品 volixibat，用於治療患有膽汁淤積性肝病的成年患者。
公司簡介
公司代碼MIRM
公司名稱Mirum Pharmaceuticals Inc
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
員工數量322
證券類型Ordinary Share
年結日Jul 18
公司地址989 East Hillsdale Boulevard, Suite 300
城市FOSTER CITY
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94404
電話16506674085
網址https://mirumpharma.com/
公司代碼MIRM
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
+7.00%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
35.95K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
+57.03%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
5.65K
--
Mr. Andrew Mckibben
Mr. Andrew Mckibben
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
+7.00%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
35.95K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
股東統計
更新時間: 7月28日 週一
更新時間: 7月28日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
13.72%
Janus Henderson Investors
10.26%
BlackRock Institutional Trust Company, N.A.
6.09%
BVF Partners L.P.
5.65%
The Vanguard Group, Inc.
5.11%
Other
59.18%
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
13.72%
Janus Henderson Investors
10.26%
BlackRock Institutional Trust Company, N.A.
6.09%
BVF Partners L.P.
5.65%
The Vanguard Group, Inc.
5.11%
Other
59.18%
股東類型
持股股東
佔比
Investment Advisor
34.15%
Investment Advisor/Hedge Fund
33.35%
Hedge Fund
22.34%
Private Equity
14.20%
Research Firm
4.78%
Venture Capital
3.32%
Individual Investor
1.90%
Sovereign Wealth Fund
0.95%
Pension Fund
0.87%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
457
57.63M
116.34%
-5.10M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
2023Q3
337
55.34M
123.03%
+4.03M
2023Q2
315
43.67M
117.43%
-6.40M
2023Q1
289
41.51M
112.21%
-7.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
6.80M
13.72%
+3.07M
+82.21%
Mar 31, 2025
Janus Henderson Investors
5.08M
10.26%
+83.18K
+1.66%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
3.02M
6.09%
-81.87K
-2.64%
Mar 31, 2025
BVF Partners L.P.
2.80M
5.65%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
5.11%
+115.33K
+4.77%
Mar 31, 2025
Eventide Asset Management, LLC
2.53M
5.1%
-79.94K
-3.07%
Mar 31, 2025
Novo Holdings A/S
1.50M
3.03%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.49M
3.02%
+112.94K
+8.17%
Mar 31, 2025
Citadel Advisors LLC
1.45M
2.92%
-65.19K
-4.31%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.38M
2.79%
-8.29K
-0.60%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
2%
ALPS Medical Breakthroughs ETF
1.7%
Invesco Dorsey Wright Healthcare Momentum ETF
1.31%
Tema Heart & Health ETF
0.9%
Federated Hermes MDT Small Cap Core ETF
0.8%
First Trust Innovation Leaders ETF
0.67%
First Trust Small Cap Growth AlphaDEX Fund
0.62%
Innovator IBD 50 Fund ETF
0.5%
SPDR S&P Biotech ETF
0.48%
First Trust Small Cap Core Alphadex Fund
0.34%
查看更多
Virtus LifeSci Biotech Products ETF
佔比2%
ALPS Medical Breakthroughs ETF
佔比1.7%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.31%
Tema Heart & Health ETF
佔比0.9%
Federated Hermes MDT Small Cap Core ETF
佔比0.8%
First Trust Innovation Leaders ETF
佔比0.67%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.62%
Innovator IBD 50 Fund ETF
佔比0.5%
SPDR S&P Biotech ETF
佔比0.48%
First Trust Small Cap Core Alphadex Fund
佔比0.34%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
